CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,430,016 | -18.1% | 88,300 | +1.0% | 0.00% | 0.0% |
| Q2 2023 | $2,965,482 | +1.3% | 87,400 | +7.4% | 0.00% | 0.0% |
| Q1 2023 | $2,928,772 | -27.2% | 81,400 | -9.9% | 0.00% | -33.3% |
| Q4 2022 | $4,024,671 | +62.4% | 90,300 | +2.4% | 0.00% | +50.0% |
| Q3 2022 | $2,479,000 | +4.2% | 88,200 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $2,378,000 | -20.8% | 88,200 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $3,004,000 | -5.1% | 88,200 | +7.7% | 0.00% | 0.0% |
| Q4 2021 | $3,165,000 | -31.3% | 81,900 | -4.0% | 0.00% | -33.3% |
| Q3 2021 | $4,605,000 | +57.9% | 85,300 | -2.2% | 0.00% | +50.0% |
| Q2 2021 | $2,916,000 | +56.6% | 87,200 | -3.5% | 0.00% | +100.0% |
| Q1 2021 | $1,862,000 | +20.1% | 90,400 | +2.1% | 0.00% | 0.0% |
| Q4 2020 | $1,551,000 | – | 88,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |